HomeCompareBAX vs ARES

BAX vs ARES: Dividend Comparison 2026

BAX yields 2.28% · ARES yields 4.37%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARES wins by $2929.62M in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
ARES
ARES
● Live price
4.37%
Share price
$107.66
Annual div
$4.71
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2929.64M
Annual income
$2,806,406,662.94
Full ARES calculator →

Portfolio growth — BAX vs ARES

📍 ARES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXARES
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + ARES cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
ARES pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
ARES
Annual income on $10K today (after 15% tax)
$371.87/yr
After 10yr DRIP, annual income (after tax)
$2,385,445,663.50/yr
At 15% tax rate, ARES beats the other by $2,385,445,654.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + ARES for your $10,000?

BAX: 50%ARES: 50%
100% ARES50/50100% BAX
Portfolio after 10yr
$1464.83M
Annual income
$1,403,203,336.60/yr
Blended yield
95.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARES right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
ARES
Analyst Ratings
1
Strong
15
Buy
5
Hold
Consensus: Buy
Price Target
$179.25
+66.5% upside vs current
Range: $148.00 — $215.00
Altman Z
1.5
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
ARES buys
0
No recent congressional trades found for BAX or ARES in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXARES
Forward yield2.28%4.37%
Annual dividend / share$0.36$4.71
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%100%
Portfolio after 10y$20.6K$2929.64M
Annual income after 10y$10.26$2,806,406,662.94
Total dividends collected$602.00$2920.90M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$19.75$179.25

Year-by-year: BAX vs ARES ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrARES PortfolioARES Income/yrGap
1← crossover$10,866$166.33$11,575$874.98$709.00ARES
2$11,750$123.31$14,278$1,893.05$2.5KARES
3$12,664$90.97$19,643$4,364.80$7.0KARES
4$13,617$66.89$32,241$11,223.63$18.6KARES
5$14,619$49.07$68,932$34,434.38$54.3KARES
6$15,679$35.94$211,368$137,610.38$195.7KARES
7$16,802$26.30$1,014,866$788,702.55$998.1KARES
8$17,998$19.23$8,164,206$7,078,299.39$8.15MARES
9$19,272$14.05$115,169,668$106,433,966.79$115.15MARES
10$20,631$10.26$2,929,638,207$2,806,406,662.94$2929.62MARES

BAX vs ARES: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

ARESStock

Ares Management Corporation operates as an alternative asset manager in the United States, Europe, and Asia. The company's Tradable Credit Group segment manages various types of investment funds, such as commingled and separately managed accounts for institutional investors, and publicly traded vehicles and sub-advised funds for retail investors in the tradable and non-investment grade corporate credit markets. Its Direct Lending Group segment provides financing solutions to small-to-medium sized companies. The company's Private Equity Group segment focuses on majority or shared-control investments primarily in under-capitalized companies. Its Real Estate Group segment invests in new developments and the repositioning of assets, with a focus on control or majority-control investments; and originates and invests in a range of self-originated financing opportunities for middle-market owners and operators of commercial real estate. The firm was previously known as Ares Management, L.P. Ares Management Corporation was founded in 1997 and is headquartered in Los Angeles, California with additional offices in the United States, Europe and Asia. Ares Management GP LLC is the general partner of the company.

Full ARES Calculator →
📬

Get this BAX vs ARES comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.